Post by Dan Fletcher on Sept 2, 2011 20:32:37 GMT -5
In dogs and cats with ROSC after cardiac arrest (P), does the use of metabolic protectants (Ethyl pyruvate; PARP, mitochondrial protectants) (I) as opposed to standard care (C) improve outcome (e.g. survival with good neurological function)?